Our institute has won the FDA recognitions (ODD and PDD) of two new compounds for the treatments of rare Diseases (Rett and Leigh).
Read MoreOur latest research entitled "Plasmalogen-Mediated Activation of GPCR21 Regulates Cytolytic Activity of NK Cells against the Target Cells" on boosting human natural killer cells to fight against virus and cancer cells has been Published in the official journal of American Association of Immunology (AAI).
Read MoreDevelopment of a new synthesis method for plasmalogens with potential therapeutic applications.
Development of a new synthetic plasmalogen analog (KIT-13) with potential therapeutic applications for Rett Syndrome.
Development of a new compound (KIT-20) with potential therapeutic applications for Leigh Disease.
Published in Frontiers in Cell and Developmental Biology, 2024.
Download PDFPublished in Frontiers in Cell and Developmental Biology, 2023.
Download PDFPublished in Journal of Immunology, 2022.
Download PDFDate: May 15-16, 2025
Location: Nippondaira Hotel, Shizuoka, Japan
DetailsDate: July 24-27, 2025
Location: Toki Messe, Niigata, Japan.
DetailsDate: June 9-11, 2025
Location: Boston, Massachusetts
Details